Efficacy and safety of Yukmijihwang-tang in patients with type 2 diabetes who have microalbuminuria- a pilot study

Status

Recruiting

Phases

Unknown

Study type

Interventional

Source

CRIS

Registry ID

KCT0001853

Enrollment

Registered

2016-03-18

Start date

2016-03-17

Completion date

Unknown

Last updated

2019-03-11

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

None listed

Interventions

Drug : Type 2 Diabetes mellitus who have microalbuminuria(30-300mg/day) and have adequeate glycemic control (Hb a1c <9%) following the treatement will be included in this study. After completing the s

Eligibility

Sex/Gender

All

Inclusion criteria

Inclusion criteria: Patients are eligible to be included in the study only if they meet all of the following criteria; ? Subject who is more than18 years of age and younger than 80 years of age has been diagnosed with type 2 diabetes mellitus. ? Subject who have micromabumiuria (30-300mg/day) ? Subject agrees to participate in this study and writes Informed consent.

Exclusion criteria

Exclusion criteria: Patient will be excluded from the study if they meet any of the following criteria; ?Subject has a Hb A1c value more than 9%, hyperglycemia or symptom due to poorly controlled glucosefor at least 3 months, and should be required more intense medications based on the investigator's judgement. ?Subjects is currently receving or changing Angiotensin-Converting Enzyme Inhibitors or Angiotensin II Receptor Blockers ?Subject is participating in another clinical study. ?Subject has a history of an active malignancy, Chronic kidney disease stage 4 or more, serious conditions such as hepatic or heart disease ?Subject is the female of childbearing potential who are pregnant, breast-feeding, or not using adequate contraceptive methods ?Subject currently has a history of severe physical activity, fever, elevation of blood pressure, or high protein diet. ?Subject has episodes of nausea, vomiting, or acute gastrointestinal symptom within the 2 weeks before

Design outcomes

Primary

Measure	Time frame
Microalbuminuria	—

Secondary

Measure	Time frame
cystatin C;N-acetyl-b-D-glucosaminidase;urinary neutrophil gelatinase-associated ipocalin; HbA1c;fructosamin;fasting plasma glucose	—

Countries

Korea, Republic of

Contacts

Public Contacteun Ko

Daegu Catholic University Medical Center

keylgh0905@naver.com

Outcome results